ArticleTurk patoloji dergisi2026
Evaluation of the Role of Taurine in Mitigating the Deleterious Effects of Tartrazine on the Kidneys in Rats: Experimental Study.
Article in Turk patoloji dergisi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTartrazine (TZ) is an anionic azo dye widely used to color food products, pharmaceuticals, and cosmetics; however, its harmful effects on the kidneys are still unclear and need to be confirmed. Meanwhile, taurine (TA) is a natural antioxidant amino acid that can provide protection against various forms of glomerulonephritis. Our aim was to study the structural, and biochemical effects of TZ on the kidney and evaluate the potential protection provided by taurine. MATERIAL AND
methodsWe used 28 adult male albino rats equally divided into 4 groups. The control group did not receive TZ or TA. The TA group received 100 mg/kg/day of TA. The TZ group received 100 mg/kg/day of TZ dissolved in distilled water. The TZ/TA group received both TZ and TA. Animal blood samples were obtained to estimate blood urea, creatinine, and random glucose levels. Kidneys samples were examined for structure as well as oxidative enzymes and kidney injury molecule 1 (KIM-1).
resultsCompared to the control group, the TZ group showed hyperglycemia, increased markers of oxidative stress, and shrunken, lobulated glomeruli with mesangial expansion, pyknosis, and vacuolation in the tubular lining. There was also strong immunoreactivity for PCNA and caspase-3, a thickened glomerular capillary basement membrane lacking fenestrations, swollen mitochondria with destructed cristae, and increased expression of the KIM-1. In the TZ/TA group, the convoluted tubules mostly retained the normal histological structure, but some tubules still showed a wide lumen and nuclear pyknosis of lining cells. Oxidative markers and random blood glucose levels were significantly reduced.
conclusionTZ is suggested to cause adverse kidney effects in rats, including kidney injury and structural changes, which can be mitigated by co-administration with TA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.